Form 4: Esperion Therapeutics Director Acquires Stock Options

Nicole Vitullo, a director at Esperion Therapeutics, acquired stock options for 65,000 shares at an exercise price of $2.25 on May 23, 2024.

Summary

• On May 23, 2024, Nicole Vitullo, a director of Esperion Therapeutics, Inc., was granted stock options to purchase 65,000 shares of common stock.
• The exercise price of these options is $2.25 per share.
• The options vest on the earlier of May 23, 2025, or the company's next annual meeting of stockholders following May 23, 2024.
• The options expire on May 23, 2034.
• The transaction was reported on a Form 4 filing with the SEC.
• Vitullo has granted Sheldon Koenig and Benjamin Looker power of attorney to execute SEC filings on her behalf.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing. The sentiment is neutral as it simply reports a transaction.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC filing related to insider transactions. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.

Stakeholder Impact

• The granting of stock options to a director could potentially align the director's interests with those of the shareholders.

Key Dates